Neuren Pharmaceuticals (ASX:NEU) has requested an immediate trading halt on its shares, pending an update regarding US Food and Drug Administration (FDA) feedback on its NNZ-2591 treatment for Pitt Hopkins syndrome and hypoxic-ischemic encephalopathy, according to a Wednesday Australian bourse filing.
The trading halt will remain in place until either the market opens on Friday or the company releases an update, whichever comes first, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.